Arcutis Biotherapeutics to Present at Major Healthcare Conference
Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a biopharmaceutical company in the commercial stage that specializes in immuno-dermatology innovations, has announced its participation in a significant healthcare conference. This event will provide an opportunity for the company to connect with key stakeholders and share its advancements in the dermatological sector.
Event Participation Details
As part of its engagement efforts, Arcutis management will take part in a fireside chat during the conference. Here are the details:
- Fireside Chat Date: Thursday, September 5
- Fireside Chat Time: 1:50 PM ET
For those interested in following the presentations and discussions, the conference webcast will be available through the Events section on the company’s official website. Additionally, a recorded replay of the discussion will be accessible for 180 days after the event, allowing stakeholders to revisit key insights at their convenience.
About Arcutis Biotherapeutics
Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) is a medical dermatology company in the commercial stage, committed to delivering significant innovations that address the urgent needs of individuals suffering from immune-mediated dermatological diseases. The company is dedicated to tackling the persistent challenges faced by patients, focusing on the most pressing conditions within dermatology.
Innovative Product Portfolio
Arcutis has built a strong portfolio that includes three FDA-approved products. These offerings leverage Arcutis's unique dermatology development platform, which combines years of expertise to create differentiated therapies that target biologically validated pathways. The company’s commitment to advancing treatment methodologies aims to improve the quality of life for patients dealing with various dermatological challenges.
Pipeline for Future Developments
In line with its mission to provide effective solutions, Arcutis has a robust pipeline filled with clinical programs that address a wide range of inflammatory dermatological conditions. These include common issues such as scalp and body psoriasis, atopic dermatitis, and alopecia areata, all of which pose significant challenges for patients. The clinical development of these treatments positions Arcutis as a leader in innovation within dermatological care.
Company Commitment
Arcutis is devoted to ensuring that patients receive the highest quality of care through its innovative products and ongoing research initiatives. The company strives to address the chronic challenges in dermatology, establishing itself as a key player in the biopharmaceutical industry.
Contact Information
For further information, individuals can reach out to:
Media Inquiries:
Amanda Sheldon, Head of Corporate Communications
Email: media@arcutis.com
Investor Relations:
Latha Vairavan, Vice President, Finance and Investor Relations
Email: ir@arcutis.com
Frequently Asked Questions
What is Arcutis Biotherapeutics known for?
Arcutis Biotherapeutics is known for its focus on innovations in immuno-dermatology and the development of therapies for immune-mediated dermatological diseases.
When will Arcutis hold its fireside chat?
The fireside chat is set for Thursday, September 5 at 1:50 PM ET.
How can stakeholders access the conference?
Stakeholders can access the conference webcast through the Events section on Arcutis's official website.
What types of diseases does Arcutis focus on?
Arcutis focuses on treating various inflammatory dermatological conditions, including psoriasis, atopic dermatitis, and alopecia areata.
Who can I contact for media inquiries?
For media inquiries, you can reach Amanda Sheldon at media@arcutis.com.
